Document Detail

Sirolimus versus paclitaxel-eluting stents in small coronary vessels: long-term outcomes from a single-center registry.
MedLine Citation:
PMID:  20150821     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Several studies showed that small vessel diameter is a determinant of increased risk of adverse events after stenting. The efficacy of different drug-eluting stent types implanted in small vessels has still not been established. The aim of the present observational study was to compare long-term clinical outcomes after sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES) implantation in lesions located in small coronary vessels. METHODS: For the purpose of this analysis patients undergoing SES or PES implantation in vessels with diameter 2.5 mm or less, from May 2002 to December 2006, were included. Long-term rates of major adverse cardiac events were evaluated and compared between the two groups. Independent predictors of major adverse cardiac events were also investigated. RESULTS: A total of 336 patients were included, 225 were treated only with SES and 111 only with PES. During a mean follow-up of 23.3 +/- 12.1 months the major adverse cardiac events rates were 12.8 versus 13.6%, P = 0.98 in SES versus PES groups, respectively. The rates of target lesion revascularization (8.0 versus 6.3%, P = 0.75), mortality (3.5 versus 4.5%, P = 0.88) and myocardial infarction (2.6 versus 4.5%, P = 0.41) were similar between SES and PES, respectively. The overall thrombosis rate was also not significantly different in SES and PES groups (1.3% SES versus 4.5% PES, P = 0.12). CONCLUSION: In this study SES and PES provided similar long-term results after treatment of lesions in small vessels. Nevertheless, larger randomized studies are needed to confirm these findings.
Rita Bucalo; Piera Capranzano; Giorgio Conti; Davide Capodanno; Cettina Ruperto; Anita Blundo; Anna Caggegi; Claudia Tamburino; Alessandra Sanfilippo; Corrado Tamburino
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of cardiovascular medicine (Hagerstown, Md.)     Volume:  11     ISSN:  1558-2035     ISO Abbreviation:  J Cardiovasc Med (Hagerstown)     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-03-30     Completed Date:  2010-06-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101259752     Medline TA:  J Cardiovasc Med (Hagerstown)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  365-8     Citation Subset:  IM    
Institute of Cardiology Ferrarotto Hospital, University of Catania, Catania, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Coronary Artery Disease / drug therapy*,  pathology
Coronary Vessels / pathology
Drug-Eluting Stents*
Middle Aged
Organ Size
Paclitaxel / therapeutic use*
Retrospective Studies
Sirolimus / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Aortic root surgery in Marfan syndrome: Bentall procedure with the composite mechanical valved condu...
Next Document:  Spontanous periodic breathing is associated with sympathetic hyperreactivity and baroreceptor dysfun...